Dr. Machiels on Pembrolizumab in Head and Neck Cancer

Jean-Pascal Machiels, MD
Published: Thursday, Jun 22, 2017



Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses pembrolizumab (Keytruda) in patients with head and neck cancer.

A hope with pembrolizumab is to administer it to patients earlier in their treatment, explains Machiels. Additionally, looking at combinations with checkpoint inhibitors can have a potential impact on treatment.
 


Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses pembrolizumab (Keytruda) in patients with head and neck cancer.

A hope with pembrolizumab is to administer it to patients earlier in their treatment, explains Machiels. Additionally, looking at combinations with checkpoint inhibitors can have a potential impact on treatment.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x